Better Survival For Women With Breast Cancer -New Evidence On Chemotherapy

September 18, 1998

New findings published in today's* (Friday 18 September) Lancet show that treating breast cancer with cell-killing drugs ("chemotherapy") improves long-term survival even if the cancer has not already spread to the local lymph glands. These benefits of chemotherapy are substantial for women aged under 50 at diagnosis, but survival is also improved for women in their 50s and 60s.

Even after successful surgery, breast cancer cells may remain undetected in the body. There are two main ways of treating these. One is hormonal therapy: for example, tamoxifen can be used to block hormone receptors on the cancer cells and so interfere with their growth. The other way is to use a cocktail of drugs to kill the cancer cells ("chemotherapy").

In the largest ever randomised study of chemotherapy for cancer, an international collaboration organised by the Imperial Cancer Research Fund's Clinical Trial Service Unit at Oxford University, followed 18,000 women with breast cancer.

Among women aged under 50 whose cancer had already spread to the local lymph glands at the time of surgery ("node-positive"), some months of chemotherapy typically prevented about 11 deaths during the next 10 years for every 100 women treated. But, among younger women with no evidence of disease spread, the benefits of chemotherapy were also substantial - about 7 fewer deaths per 100 treated. Chemotherapy produced a small, but real, improvement in survival - of about 2-3 lives saved per 100 - for women in their 50s and 60s whose cancer was either node-positive or node-negative.

Professor Rory Collins from Oxford University said: "We already knew that chemotherapy improves the chances of survival for a young woman with breast cancer which has spread to the local lymph glands. Now we know that this treatment is beneficial even if the cancer appears to be confined to her breast."

The study shows that, even if tamoxifen is to be given, chemotherapy produces additional benefit. Moreover, chemotherapy improves survival among women whose breast cancer is not hormone-sensitive, for whom there is as yet no clear evidence of benefit with tamoxifen.

The collaboration brought together detailed information from 47 randomised studies conducted over the past two decades around the world. There was no evidence of any survival advantage from using more than about 3-6 months of chemotherapy.

Dr Michael Clarke, of the Imperial Cancer Research Fund's Oxford Unit and the study coordinator, said: "This huge study provides uniquely reliable evidence about the effects of chemotherapy. In terms of recurrence and survival, the balance of the long-term benefits and risks favours some months of chemotherapy for a wide range of women with early breast cancer."

__________________________________________________
* Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 19 September 1998

Breast Cancer Awareness Month

One in 12 women in the UK will get breast cancer at some time in their lives - nearly 32,500 new cases every year. Breast cancer is the most common cancer in women in the UK.

The Imperial Cancer Research Fund is working hard to find new answers to breast cancer and currently spends more than £5 million a year on research into the disease. Along with other organisations concerned with the breast cancer, Imperial Cancer is dedicating October to raising awareness of, and further funds for, vital research into the disease.

Imperial Cancer Research Fund - Background Brief

The Imperial Cancer Research Fund is dedicated to the understanding, prevention, treatment and cure of all forms of cancer. Its 1,000 scientists and doctors are at the forefront of the worldwide effort to defeat the disease. The charity relies almost totally on voluntary funding to carry out its vital work.

Web site: www.icnet.uk

Further Information:
Stacey Adams tel: +44-171-269-3141, e-mail: s.adams@icrf.icnet.uk
Christine Suggars tel: +44-171-269-3614 (work), +44-1480-217110 (home), 04325-253987 (pager), 0498-806839 (mobile). email: c.suggars@icrf.icnet.uk
Press office fax: +44-171-269-3262
-end-


Imperial Cancer Research Fund

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.